Roche Diagnostics Corporation Cell Marque, Cox-2 (Sp21)

Roche Diagnostics Corporation cell marque, cox-2 (sp21); cyclooxygenase-2 catalyzes the conversion of arachidonic acid to prostaglandin h2 in the first step in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. cox-2 inhibition by nonsteroidal antiinflamatory agents has been shown to decrease angiogenesis, and tumor growth, and promote apoptosis. cox-2 overexpression has been associated with increased microvascular density, and vegf protein expression in head and neck squamous cell carcinoma and is a poor prognostic indicator in this entity as well. cox-2 overexpression has also been suggested as a poor prognostic indicator in carcinomas of the colon, breast, pancreas, and adenocarcinoma of the lung. - ROCHMSD (Additional S&H or Hazmat Fees May Apply)